FONT-SIZE Plus   Neg

HP Realigns To Create Printing And Personal Systems Group - Quick Facts

HP (HPQ) announced an organizational realignment to improve performance and drive profitable growth across the entire HP portfolio. HP said its Imaging and Printing Group or IPG and its Personal Systems Group or PSG are joining forces to create the Printing and Personal Systems Group, while the combined entity would be led by Todd Bradley, who has served as the executive vice president of PSG since 2005.

Vyomesh Joshi, executive vice president of IPG, is retiring after a highly accomplished 31-year career at HP.

The company said that combining these two entities would rationalize its go-to-market strategy, branding, supply chain and customer support worldwide. HP said this realignment is anticipated to provide opportunities for cost savings and accelerate HP's ability to pursue profitable growth and reinvest in the business. Further to combining PSG and IPG, HP also is taking steps to unify and streamline certain key business functions.

Also, HP said it would unify its Marketing functions across business units under Marty Homlish, executive vice president and chief marketing officer, HP.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Visa Inc. (V) on Monday reported an increase in profit for the fourth quarter, as revenues jumped driven largely by increase in customer spending and inclusion of Europe business. Earnings and revenues trumped Wall Street expectations. Foster City, California-based Visa's fourth-quarter profit rose... As Sony Corp. prepares to launch the new PlayStation 4 Pro gaming console on November 10, several new games that are compatible with the console have also been confirmed for launch. Game developers are readying to provide PlayStation 4 Pro support for many games on PS4. Shares of Advaxis Inc. dropped more than 13 percent in pre-market activity before paring losses to just more than 5 percent after the company said that it was not able to complete the second stage of the Phase 2 GOG-0265 trial as designed due to a clinical hold that affected its clinical development programs last year.
comments powered by Disqus
Follow RTT